MetaCap

Nasus Pharma (NSRX) vs ProMIS Neurosciences (PMN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nasus Pharma (NSRX) has outperformed ProMIS Neurosciences (PMN) over the past year, losing 68.4% versus a loss of 69.9%. ProMIS Neurosciences is the larger company by market cap ($28.4 million vs $26.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NSRX-68.41%PMN-69.90%
+147%+32%-83%
Nov 21, 20251 yearNov 20, 2026
NSRX-71.73%PMN-79.61%
+58%-14%-86%
Aug 11, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NSRX versus PMN key metrics
MetricNSRXPMN
Share price$2.29$3.16
Market cap$26.82M$28.43M
1-day change-10.20%-1.56%
YTD return-74.97%-53.73%
1-year return-68.41%-69.90%
5-year return—-98.24%
EPS (TTM)$-1.20$-6.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.24B—
Net income (latest FY)$-5.86M$-39.72M
Operating margin-0.40%—
Net margin-0.47%—
52-week high$9.50$27.40
52-week low$1.98$2.78
Distance from 52-week high-75.89%-88.47%
Analyst consensusbuynone
Avg. price target upside+758.95%+1248.42%
Average volume16.80K164.88K
Shares outstanding11.71M9.00M
Employees710
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Nasus Pharma

NSRX stock →

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About ProMIS Neurosciences

PMN stock →

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

NSRX vs PMN FAQ

Which is bigger, Nasus Pharma or ProMIS Neurosciences?

ProMIS Neurosciences (PMN) is larger, with a market capitalization of $28.43M compared with $26.82M for Nasus Pharma (NSRX).

Which stock has performed better over the past year, NSRX or PMN?

NSRX returned -68.41% over the past 12 months, compared with -69.90% for PMN (price return, excluding dividends). Past performance does not predict future results.

Are Nasus Pharma and ProMIS Neurosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons